Pfizer Inc. (NYSE:PFE) Shares Purchased by Seelaus Asset Management LLC

Seelaus Asset Management LLC raised its stake in shares of Pfizer Inc. (NYSE:PFE) by 61.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 29,427 shares of the biopharmaceutical company’s stock after purchasing an additional 11,215 shares during the quarter. Seelaus Asset Management LLC’s holdings in Pfizer were worth $852,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Olistico Wealth LLC acquired a new stake in Pfizer during the second quarter valued at $25,000. MFA Wealth Advisors LLC acquired a new stake in Pfizer in the second quarter valued at approximately $29,000. Quarry LP purchased a new stake in shares of Pfizer in the second quarter valued at approximately $31,000. Financial Connections Group Inc. purchased a new position in shares of Pfizer during the 2nd quarter valued at approximately $34,000. Finally, ESL Trust Services LLC acquired a new stake in Pfizer in the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Trading Down 4.7 %

Shares of PFE stock opened at $24.80 on Friday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a twelve month low of $24.48 and a twelve month high of $31.54. The company’s 50-day moving average price is $28.64 and its 200-day moving average price is $28.64. The stock has a market cap of $140.54 billion, a price-to-earnings ratio of 33.51, a PEG ratio of 0.85 and a beta of 0.67.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. Pfizer’s revenue was up 31.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.17) EPS. As a group, equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.77%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Analyst Upgrades and Downgrades

Several analysts have recently issued reports on the stock. StockNews.com upgraded shares of Pfizer from a “buy” rating to a “strong-buy” rating in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Wells Fargo & Company lifted their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. UBS Group increased their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, five have issued a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.92.

Insiders Place Their Bets

In related news, Director Scott Gottlieb bought 1,000 shares of the stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 11.11 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.